Psychiatry

Your Article Summary

See Latest Articles

A review of the clinical pharmacology of methamphetamine
Addiction, 06/29/09

Cruickshank CC et al. - Repeated use may induce neurotoxicity, associated with prolonged psychiatric symptoms, cognitive impairment and an increased risk of developing Parkinson's disease. Abrupt cessation of repeated methamphetamine use leads to a withdrawal syndrome consisting of depressed mood, anxiety and sleep disturbance.

• Relevant literature was identified through a PubMed search.
• Additional literature was obtained from relevant books and monographs.

• The mean elimination half-life for methamphetamine is approximately 10 hours, with considerable inter-individual variability in pharmacokinetics.
• Direct effects at low-to-moderate methamphetamine doses (5-30 mg) include arousal, positive mood, cardiac stimulation and acute improvement in cognitive domains such as attention and psychomotor coordination.
• At higher doses used typically by illicit users (≥50 mg), methamphetamine can produce psychosis.
• Its hypertensive effect can produce a number of acute and chronic cardiovascular complications.
• Acute withdrawal lasts typically for 7-10 days, and residual symptoms associated with neurotoxicity may persist for several months.

Today in Mood Disorders...keeping you current

Receive free subspecialty "5-minute updates" via email

Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09

Management of agitation and aggression associated with Alzheimers disease: controversies and possible solutions
Current Opinion in Psychiatry, 10/12/09

Does Dual Antidepressant Therapy as Initial Treatment Hasten and Increase Remission from Depression
Journal of Psychiatric Practice, 09/29/09

See All of Mood Disorders

Today in Neuro/Psych Pharmacol...keeping you current

Receive free subspecialty "5-minute updates" via email

Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09

Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09

Does Dual Antidepressant Therapy as Initial Treatment Hasten and Increase Remission from Depression
Journal of Psychiatric Practice, 09/29/09

See All of Neuro/Psych Pharmacol

Today in Personality Disorders...keeping you current

Receive free subspecialty "5-minute updates" via email

Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09

Management of agitation and aggression associated with Alzheimers disease: controversies and possible solutions
Current Opinion in Psychiatry, 10/12/09

Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder
International Clinical Psychopharmacology, 10/23/09

See All of Personality Disorders

Today in Schizophrenia/Psychosis...keeping you current

Receive free subspecialty "5-minute updates" via email

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09

A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia
Journal of Psychopharmacology, 10/19/09

Acupuncture for schizophrenia: a systematic review and meta-analysis
International Journal of Clinical Practice, 10/16/09

See All of Schizophrenia/Psychosis

Today in Substance Abuse...keeping you current

Receive free subspecialty "5-minute updates" via email

Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09

Adverse health effects of non-medical cannabis use
The Lancet, 10/19/09

Improving Clinical Outcomes in Treating Heroin Dependence: Randomized, Controlled Trial of Oral or Implant Naltrexone
Archives of General Psychiatry, 10/09/09

See All of Substance Abuse